Reserving full karyotyping for the 10% of fetuses with first trimester nuchal translucency (NT) measurements of 4 mm or more and using quantitative fluorescent polymerase chain reaction (qf-PCR) for less suspicious samples may be an effective screening strategy that provides rapid results at significant cost savings, according to a recent observational study.
Reserving full karyotyping for the 10% of fetuses with first trimester nuchal translucency (NT) measurements of 4 mm or more and using quantitative fluorescent polymerase chain reaction (qf-PCR) for less suspicious samples may be an effective screening strategy that provides rapid results at significant cost savings, according to a recent observational study.
Researchers from the United Kingdom evaluated approximately 17,500 chorionic villus samples obtained after assessing risk for trisomy 21 by measurement of fetal NT thickness at 11 to 13 weeks' gestation. They analyzed samples by full karyotyping and by qf-PCR for chromosomes 13, 18, 21, X, and Y.
They found the fetal karyotype to be normal in approximately 89% of cases and abnormal in the remaining 11%. The researchers calculated that while relying entirely on karyotyping reveals all clinically significant chromosomal abnormalities and relying entirely on qf-PCR identifies 97.9%, the combination strategy identifies 99% of significant abnormalities at 60% of the cost of full karyotyping for all.
Disparities in kidney care access for pregnant patients
December 11th 2023A recent study highlights significant disparities in kidney transplant and nephrology care access for pregnant patients with end-stage kidney disease, revealing reduced survival rates and limited access to crucial care compared to non-pregnancy-related causes.
Read More
Mediterranean diet linked to improved pregnancy outcomes
December 8th 2023A comprehensive meta-analysis scrutinizes the Mediterranean diet's impact on female reproductive health, uncovering compelling evidence that links this nutritional approach to a significant reduction in adverse pregnancy outcomes.
Read More
FDA grants IND clearance to DARE-VVA1 for dyspareunia
December 7th 2023Daré Bioscience's tamoxifen-based therapy, DARE-VVA1, secures FDA clearance for an investigational new drug application, offering hope for women with contraindications to estrogen therapies suffering from the underdiagnosed condition of vulvar and vaginal atrophy.
Read More